SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is experiencing significant volatility driven by President Trump's recent actions regarding Greenland and subsequent threats of substantial tariffs against European nations. The market community is sharply divided, with many bears predicting a major downturn, while bulls are actively preparing to "buy the dip" amidst broader uncertainty over global trade relations and geopolitical stability.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as renewed geopolitical tensions stemming from discussions around Greenland and potential tariffs from former President Trump on European goods spark significant market conversation. The community is split between fears of a deeper market pullback and those anticipating a swift "buy the dip" recovery, driven by the index's historical resilience amidst political volatility and upcoming tech earnings.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as its highly engaged community champions the "OG meme" narrative of Rage Comics, positioning it as a "foundational meme reset" for the current market cycle. This dedicated base actively builds an ecosystem with platforms like RageMaker and RageGames, expressing strong conviction and urging fellow enthusiasts to "Return to the Memes" and "Rage On" to reclaim leadership in the meme coin space.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as Elon Musk announces rapid advancements in AI chip development (AI5, AI6) and plans for a "TeraFab" to boost production, sparking widespread community debate. This ambitious AI push is met with bullish excitement for future robotaxi and robotics potential, while skeptics point to reported softness in global vehicle sales across various regions and intensifying competition. The upcoming earnings report serves as a key point of focus for investors evaluating these contrasting narratives.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy ($SWEAT) is actively trending as its move-to-earn crypto model, rewarding users for physical activity, gains renewed community interest amidst recent token burns aimed at boosting scarcity. Investors are discussing its long-term potential, pointing to staking opportunities and expanding Web3 ecosystem utility, with many urging others not to overlook its future growth.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is experiencing a significant surge to new all-time highs, propelled by escalating geopolitical tensions, including recent tariff threats against Europe and broader global instability. The community is actively discussing whether this rally reflects a critical flight to safety amidst concerns over the US dollar's strength and eroding confidence in fiat currencies, with many anticipating sustained upward momentum for precious metals.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending due to rising geopolitical tensions between the U.S. and Europe, sparked by discussions around potential tariffs related to Greenland, with many attributing the recent market dip to these political actions. The community remains divided, with some anticipating further declines amid broad selling pressure, while others view the current pullback as a buying opportunity, especially with the Digital Asset Market Clarity Act markup scheduled.

Venus Concept, Inc. is a global medical technology company, which engages in the business of developing, commercializing, and selling minimally invasive and non-invasive medical aesthetic and hair restoration technologies. It operates under the United States and International geographical segments. The company was founded on November 22, 2002 and is headquartered in Toronto, Canada.

Venus Concept Inc

Venus Concept (VERO) is trending amid intense debate following Madryn Asset Management's reported 91% ownership stake. Bulls are aggressively pushing the narrative that this unprecedented "float lock" will lead to astronomical gains by neutralizing short-selling pressure. However, a strong contingent of skeptics warns of weak company fundamentals and suggests the large stake could ultimately lead to privatization or delisting, casting the recent surge as an unsustainable pump-and-dump.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is drawing immense attention as renewed geopolitical interest in Greenland by former President Trump intensifies the focus on the island's vast rare earth deposits. The community is actively discussing CRML's strategic position with its Tanbreez project and significant international processing partnerships, anticipating its crucial role in securing critical mineral supply chains.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as discussions erupt over former President Trump's recent stance on Greenland, including potential tariffs on European nations and perceived links to the Nobel Peace Prize. The community is sharply divided, with some expressing concern over escalating geopolitical tensions and market uncertainty, while others laud the assertive "America First" strategy. These developments are amplifying debates on global trade relations and international alliances.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biohaven (NYSE:BHVN) Stock Price Up 8% - Still a Buy?

Biohaven (NYSE:BHVN) Trading 8% Higher - Here's Why...

Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference Biohaven Highlights...

Morgan Stanley Issues Pessimistic Forecast for Biohaven (NYSE:BHVN) Stock Price

Morgan Stanley reduced their price target on shares of Biohaven from $26.00 to $21.00 and set an "overweight" rating on the stock in a research report on Tuesday...

Biohaven Ltd. (NYSE:BHVN) Receives Average Recommendation of "Moderate Buy" from Analysts

Biohaven Ltd. (NYSE:BHVN - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eighteen analysts that are covering the firm, Marketbeat reports. One investment analyst has rated...

Biohaven (NYSE:BHVN) Trading Down 8% - Here's What Happened

Biohaven (NYSE:BHVN) Shares Down 8% - Here's Why...

Biohaven (NYSE:BHVN) Trading 3.6% Higher - Here's What Happened

Biohaven (NYSE:BHVN) Shares Up 3.6% - What's Next...

Biohaven (NYSE:BHVN) Shares Gap Down - What's Next?

Biohaven (NYSE:BHVN) Shares Gap Down - Here's What Happened...

<ul class="summary-bullets"><li>Analyst Myles Minter noted that the company’s pivotal Phase III study of BHV-7000 in focal-onset epilepsy in the first half of 2026 will be the critical factor.</li><li>Citi emphasized that the study was expected to be difficult, and the company’s epilepsy program holds a higher probability of success.</li><li>H.C. Wainwright was unsurprised by the depression study outcome but advised caution leading into the seizures data readout.</li></ul>Biohaven Pharmaceuticals’ (BHVN) disappointing Phase II results for BHV-7000 in major depressive disorder have raised caution among Wall Street firms but have not completely shaken confidence in the company’s broader pipeline.The company announced on Wednesday that its Phase 2 study of BHV-7000 did not meet its primary endpoint.&nbsp;<h2 class="st-heading-2">Analyst Reactions&nbsp;&nbsp;</h2>William Blair expected challenges with the depression study, given difficulties in executing trials and the prevalence of placebo effects, according to TheFly.Analyst Myles Minter maintained a ‘Market Perform’ rating on the stock, citing that the company’s pivotal Phase III study for BHV-7000 in focal onset epilepsy in the first half of 2026 will be the critical factor in determining the drug’s effectiveness in an extended-release formulation.&nbsp;He added that the failure has minimal implications for&nbsp;Biohaven’s competitor, Xenon Pharmaceuticals' (XENE) depression trials.<h2 class="st-heading-2">Focus Shifts To 2026 Seizure Study</h2>According to Samantha Semenkow of Citi, who maintained a ‘Buy’ rating with a $14 price target, the market is more focused on the upcoming Phase III epilepsy results for BHV-7000 in 2026 than on the Phase II depression data.&nbsp;She emphasized that the earlier study was expected to be difficult, and the company’s epilepsy program holds a higher probability of success.&nbsp;H.C. Wainwright was unsurprised by the depression study outcome but advised caution leading into the seizures data readout. The firm maintained that the Phase II miss does not significantly impact expectations for Xenon Pharmaceuticals’ azetukalner Phase III trial in major depressive disorder.&nbsp;<h2 class="st-heading-2">What’s The Retail Mood On Stocktwits?</h2><a href="https://stocktwits.com/symbol/BHVN">Biohaven stock</a> traded over 14% lower in Friday’s premarket, and it was the top-trending equity ticker on StockTwits.&nbsp;However, retail sentiment around the stock remained in ‘bullish’ territory amid ‘extremely high’ message volume levels.&nbsp;<figure class="image"><img style="aspect-ratio:930/104;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_26_073329_png_a8c9a6c4f1.webp" alt="BHVN’s Sentiment Meter and Message Volume as of 07:30 a.m. ET on Dec. 26, 2025 | Source: Stocktwits" width="930" height="104"><figcaption>BHVN’s Sentiment Meter and Message Volume as of 07:30 a.m. ET on Dec. 26, 2025 | Source: Stocktwits</figcaption></figure>BHVN stock has declined by over 71% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/micron-stock-triples-in-2025-as-ai-memory-demand-supercharges-growth/cLeUIgNREwS">Micron Stock Triples In 2025 As AI Memory Demand Supercharges Growth: Retail Now Expects A Netflix-Like Super Rally</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Biohaven logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Biohaven’s Phase II Depression Trial Falls Short, But Analysts Downplay Impact – Wall Street Looks Ahead To Epilepsy Data

William Blair expected challenges with the depression study, given difficulties in executing trials and the prevalence of placebo effects. 

Equity

William Blair expected challenges with the depression study, given difficulties in executing trials and the prevalence of placebo effects. 


<ul class="summary-bullets"><li>The company also announced that it does not plan on additional psychiatric clinical trials and intends to prioritize its resources for other therapeutic areas including immunology, obesity and epilepsy in 2026.</li><li>BHV-7000 failed to meet its primary endpoint in a pivotal Phase II/III clinical trial for bipolar disorder in March.</li><li>Last month, FDA refused to approve the company’s drug Vyglxia in the treatment of Spinocerebellar ataxia, sparking portfolio prioritization measures.</li></ul>Shares of Biohaven Ltd. (BHVN) slumped 17% after hours on Christmas eve after the company announced that its mid-stage proof-of-concept study evaluating BHV-7000 for the treatment of major depressive disorder did not show a reduction of depressive symptoms.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/biohaven-provides-update-from-phase-2-proof-of-concept-study-with-bhv-7000-in-major-depressive-disorder-302649251.html">said</a> that no reduction in depressive symptoms were observed in the trial over six weeks as compared with placebo though trends favoring BHV-7000 were observed in some clinically relevant subgroups, including participants with more severe depression.The drug was safe and well-tolerated with adverse events mostly mild and moderate in intensity and largely resolved spontaneously, the company said.The company also announced that it does not plan on additional psychiatric clinical trials and intends to prioritize its resources for other therapeutic areas including immunology, obesity and epilepsy in 2026.BHV-7000 failed to meet its primary endpoint in a pivotal Phase II/III clinical trial for bipolar disorder in March. The company, however, is continuing the study of the drug in adult focal epilepsy.<h2 class="st-heading-2">Other Setbacks This Year</h2>The company’s setbacks this year are not limited to its psychiatry pipeline. Last month, the U.S. Food and Drug Administration <a href="https://stocktwits.com/news-articles/markets/equity/bhvn-stock-tumbles-pre-market-after-fda-refuses-approval-for-neurodegenerative-disorder-drug/cL2q0wsREGi">refused</a> to approve its drug Vyglxia in the treatment of Spinocerebellar ataxia, a neurodegenerative disorder characterized by progressive loss of voluntary motor control and atrophy of the brain’s cerebellum and brainstem. In a letter, the FDA cited issues including potential bias, design flaws, lack of pre-specification, and unmeasured confounding factors in Biohaven’s drug studies.The company subsequently announced that it will focus on three late-stage, clinical programs with the greatest potential for value generation over the next year. It also initiated strategic portfolio and cost optimization across multiple programs to achieve an approximately 60% reduction in annual direct research and development spend.The company said last month that it may pause or delay non-priority programs to maintain its cash runway.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around BHVN stayed within the ‘bearish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.A Stocktwits user dismissed the negative update as “expected” and expressed optimism for the upcoming epilepsy trial. “Good things are to come here,” they wrote.<stembedurl>https://www.stocktwits.com/Dragonfire89/message/640093489</stembedurl>Yet another user sees the company’s investigational obesity drug being another interesting catalyst besides the epilepsy trial.<stembedurl>https://www.stocktwits.com/Reneejordan001/message/640092601</stembedurl><a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/biohaven-provides-update-from-phase-2-proof-of-concept-study-with-bhv-7000-in-major-depressive-disorder-302649251.html">BHVN stock</a> is down by 71% this year and by about 70% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-dismisses-ideas-of-spacex-echostar-merger-in-road-to-going-public/cLetcgcREvr">Elon Musk Dismisses Ideas Of SpaceX-Echostar Merger In Road To Going Public: ‘No Reason To Cut Corners’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Biohaven Stock Slumps After Hours As Failed Depression Study Adds To A Brutal 2025 — Retail Eyes Epilepsy And Obesity Catalysts

The company said that no reduction in depressive symptoms were observed in the BHV-7000 trial over six weeks as compared with placebo. 

Biohaven (NYSE:BHVN) Stock Price Down 13% - What's Next?

Biohaven (NYSE:BHVN) Stock Price Down 13% - Here's What Happened...

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$1.18	--	--	N/A
Q3 '25	-$1.90	-$1.64	13.73%	BEAT
Q2 '25	-$1.90	-$1.94	-1.99%	MISSED
Q1 '25	-$1.70	-$2.17	-27.62%	MISSED
Q4 '24	-$1.57	-$1.85	-17.47%	MISSED

BHVN
Biohaven Pharmaceutical Holding Company Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest BHVN News

BHVNBiohaven Pharmaceutical Holding Company Ltd